Anti-Fibrinolytic Drugs - Haiti | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in Haiti is expected to witness a significant rise in revenue, projected to reach US$1.83m in 2024.
This market is forecasted to exhibit an annual growth rate (CAGR 2024-2029) of 4.44%, leading to a market volume of US$2.27m by 2029.
In global comparison, United States is anticipated to generate the highest revenue in this market, amounting to US$9.86bn in 2024.
Despite the limited access to healthcare and resources, Haiti has seen a growing demand for anti-fibrinolytic drugs to address the prevalent cardiovascular diseases in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Haiti has been showing positive growth in recent years.

Customer preferences: Haiti, being a developing country, has a high incidence of hemorrhagic diseases. This has led to an increasing demand for Anti-Fibrinolytic Drugs, which help in controlling bleeding by preventing the breakdown of blood clots. The drugs are widely used in surgical procedures, trauma cases, and in the treatment of hemophilia. Due to the high prevalence of these conditions in the country, the demand for Anti-Fibrinolytic Drugs has been steadily increasing.

Trends in the market: The Anti-Fibrinolytic Drugs market in Haiti has been growing at a moderate pace due to the increasing demand for these drugs. The market is dominated by a few major players who have a strong presence in the country. These players have been expanding their product portfolio to cater to the growing demand for Anti-Fibrinolytic Drugs. The market has also seen an increase in the number of generic drugs, which has led to increased competition and lower prices.

Local special circumstances: Haiti is a developing country with limited healthcare infrastructure. The country has a high incidence of hemorrhagic diseases, which has put a strain on the healthcare system. The lack of adequate healthcare facilities and trained healthcare professionals has led to a high mortality rate in the country. The government has been taking steps to improve the healthcare system, but progress has been slow. This has led to a growing demand for Anti-Fibrinolytic Drugs, which can be administered in emergency situations even in the absence of advanced healthcare facilities.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the Western Hemisphere. The country has been facing economic challenges due to political instability, natural disasters, and the COVID-19 pandemic. The healthcare sector has been particularly affected, with limited resources and inadequate funding. Despite these challenges, the demand for Anti-Fibrinolytic Drugs has been growing due to the high incidence of hemorrhagic diseases. The market has been able to sustain its growth due to the availability of low-cost generic drugs and the presence of major players who have been expanding their product portfolio.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.